Multivariate analysis using Cox regression for PFS and OS
| . | SNUH . | KCCR . | ||||||
|---|---|---|---|---|---|---|---|---|
| PFS . | OS . | PFS . | OS . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Age, y: <60 vs ≥60 | 1.532 (0.972-2.414) | .066 | 2.478 (1.386-4.431) | .002 | 1.901 (1.140-3.169) | .014 | 1.859 (1.543-2.240) | <.001 |
| Stage: 1-2 vs 3-4 | 1.987 (1.020-3.870) | .044 | 2.668 (1.040-6.848) | .041 | 1.650 (0.982-2.772) | .059 | 1.419 (1.177-1.712) | <.001 |
| CCI, points: 1-3 vs ≥4 | 2.044 (0.815-5.126) | .127 | 1.774 (0.630-5.000) | .278 | 1.179 (0.592-2.347) | .639 | 1.292 (1.036-1.612) | .023 |
| Lymphoma subtype | ||||||||
| PTCL-NOS | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
| AITL | 0.757 (0.464-1.234) | .264 | 0.561 (0.310-1.016) | .057 | 1.040 (0.602-1.795) | .889 | 0.672 (0.546-0.827) | <.001 |
| ALCL | 0.795 (0.399-1.585) | .515 | 0.648 (0.269-1.564) | .335 | 0.518 (0.236-1.137) | .101 | 0.851 (0.649-1.115) | .242 |
| Other* | 0.983 (0.449-2.149) | .965 | 0.840 (0.315-2.240) | .727 | 0.507 (0.116-2.227) | .369 | 0.995 (0.621-1.594) | .982 |
| First-line chemotherapy: Etoposide vs no | 0.739 (0.442-1.233) | .247 | 0.822 (0.200-1.588) | .550 | 0.648 (0.339-0.886) | .014 | 0.947 (0.792-1.133) | .552 |
| . | SNUH . | KCCR . | ||||||
|---|---|---|---|---|---|---|---|---|
| PFS . | OS . | PFS . | OS . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Age, y: <60 vs ≥60 | 1.532 (0.972-2.414) | .066 | 2.478 (1.386-4.431) | .002 | 1.901 (1.140-3.169) | .014 | 1.859 (1.543-2.240) | <.001 |
| Stage: 1-2 vs 3-4 | 1.987 (1.020-3.870) | .044 | 2.668 (1.040-6.848) | .041 | 1.650 (0.982-2.772) | .059 | 1.419 (1.177-1.712) | <.001 |
| CCI, points: 1-3 vs ≥4 | 2.044 (0.815-5.126) | .127 | 1.774 (0.630-5.000) | .278 | 1.179 (0.592-2.347) | .639 | 1.292 (1.036-1.612) | .023 |
| Lymphoma subtype | ||||||||
| PTCL-NOS | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
| AITL | 0.757 (0.464-1.234) | .264 | 0.561 (0.310-1.016) | .057 | 1.040 (0.602-1.795) | .889 | 0.672 (0.546-0.827) | <.001 |
| ALCL | 0.795 (0.399-1.585) | .515 | 0.648 (0.269-1.564) | .335 | 0.518 (0.236-1.137) | .101 | 0.851 (0.649-1.115) | .242 |
| Other* | 0.983 (0.449-2.149) | .965 | 0.840 (0.315-2.240) | .727 | 0.507 (0.116-2.227) | .369 | 0.995 (0.621-1.594) | .982 |
| First-line chemotherapy: Etoposide vs no | 0.739 (0.442-1.233) | .247 | 0.822 (0.200-1.588) | .550 | 0.648 (0.339-0.886) | .014 | 0.947 (0.792-1.133) | .552 |
CI, confidence interval; HR, hazard ratio; Ref, referent.
These include EATL, SPTCL, and HSTCL.